ADEN and Derm Epi-ERG

Atopic dermatitis, covid 19, and hand dermatitis

Atopic Dermatitis and Its Associations

1. Dermatol Ther. 2020 May 27:e13687. doi: 10.1111/dth.13687. Online ahead of

print.

Considerations for safety in the use of systemic medications for psoriasis and

atopic dermatitis during the COVID-19 pandemic.

Ricardo JW(1), Lipner SR(1).

Author information:

(1)Department of Dermatology, Weill Cornell Medicine, New York, New York, USA.

Coronavirus disease 2019 (COVID-19) is responsible for at least 2 546 527 cases

and 175 812 deaths as of April 21, 2020. Psoriasis and atopic dermatitis (AD)

are common, chronic, inflammatory skin conditions, with immune dysregulation as

a shared mechanism; therefore, mainstays of treatment include systemic

immunomodulating therapies. It is unknown whether these therapies are associated

with increased COVID-19 susceptibility or worse outcomes in infected patients.

In this review, we discuss overall infection risks of nonbiologic and biologic

systemic medications for psoriasis and AD and provide therapeutic

recommendations. In summary, in patients with active infection, systemic

conventional medications, the Janus kinase inhibitor tofacitinib, and biologics

for psoriasis should be temporarily held until there is more data; in uninfected

patients switching to safer alternatives should be considered. Interleukin

(IL)-17, IL-12/23, and IL-23 inhibitors are associated with low infection risk,

with IL-17 and IL-23 favored over IL-12/23 inhibitors. Pivotal trials and

postmarketing data also suggest that IL-17 and IL-23 blockers are safer than

tumor necrosis factor alpha blockers. Apremilast, acitretin, and dupilumab have

favorable safety data and may be safely initiated and continued in uninfected

patients. Without definitive COVID-19 data, these recommendations may be useful

in guiding treatment of psoriasis and AD patients during the COVID-19 pandemic.

DOI: 10.1111/dth.13687

PMCID: PMC7283778

PMID: 32458536

2. Br J Dermatol. 2020 Apr 29:10.1111/bjd.19161. doi: 10.1111/bjd.19161. Online

ahead of print.

Global reporting of cases of COVID-19 in psoriasis and atopic dermatitis: an

opportunity to inform care during a pandemic.

Mahil SK(1), Yiu ZZN(2), Mason KJ(2), Dand N(3), Coker B(4), Wall D(5)(6),

Fletcher G(6), Bosma A(7), Capon F(3), Iversen L(8), Langan SM(1)(9), Di Meglio

P(3), Musters AH(7), Prieto-Merino D(9), Tsakok T(1), Warren RB(2), Flohr C(1),

Spuls PI(7), Griffiths CEM(2), Barker J(1), Irvine AD(10), Smith CH(1);

Secure-AD and PsoProtect study groups.

Author information:

(1)St John's Institute of Dermatology, Guy's and St Thomas' NHS Foundation Trust

and King's College London, London, UK.

(2)Dermatology Centre, Salford Royal NHS Foundation Trust, The University of

Manchester, Manchester Academic Health Science Centre, NIHR Manchester

Biomedical Research Centre, Manchester, UK.

(3)St John's Institute of Dermatology within the, School of Basic & Medical

Biosciences, King's College London, London, UK.

(4)NIHR Biomedical Research Centre at Guy's and St Thomas' NHS Foundation Trust,

London, UK.

(5)Hair Restoration Blackrock, Dublin, Ireland.

(6)National and International Skin Registry Solutions (NISR), Charles Institute

of Dermatology, Dublin, Ireland.

(7)Department of Dermatology, Amsterdam Public Health, Infection and Immunity,

Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.

(8)Department of Dermatology, Aarhus University Hospital, Aarhus C, Denmark.

(9)Faculty of Epidemiology, and Population Health, London School of Hygiene and

Tropical Medicine, London, UK.

(10)Clinical Medicine, Trinity College Dublin, Dublin, Ireland.

We wish to bring your attention to the PsoPROTECT (Psoriasis Patient Registry

for Outcomes, Therapy and Epidemiology of Covid‐19 infecTion) and SECURE‐AD

(Surveillance Epidemiology of Coronavirus Under Research Exclusion‐Atopic

Dermatitis) registries; two urgent global initiatives that address an unmet need

for delineating the determinants of COVID‐19 outcomes in the common cutaneous

immune‐mediated inflammatory diseases (IMIDs) psoriasis and atopic dermatitis.

DOI: 10.1111/bjd.19161

PMCID: PMC7267275

PMID: 32348554

3. Cureus. 2020 Apr 2;12(4):e7506. doi: 10.7759/cureus.7506.

Frequent Hand Washing for COVID-19 Prevention Can Cause Hand Dermatitis:

Management Tips.

Beiu C(1), Mihai M(1), Popa L(1), Cima L(2), Popescu MN(3).

Author information:

(1)Oncologic Dermatology, Elias Emergency University Hospital, "Carol Davila"

University of Medicine and Pharmacy, Bucharest, ROU.

(2)Pharmacy, "Carol Davila" University of Medicine and Pharmacy, Bucharest, ROU.

(3)Physical Medicine and Rehabilitation, "Carol Davila" University of Medicine

and Pharmacy, Bucharest, ROU.

Coronavirus disease 2019 (COVID-19) continues to spread globally, outpacing the

capacity and resources of health systems worldwide. A therapeutic vaccine is not

yet on the rise, and preventive measures are the current approach to restraint

the transmission of cases. As the virus is highly contagious via respiratory

route (droplets from infected persons, widely spread by coughing or sneezing)

and via contact with contaminated surfaces, community transmission and spread

can be decreased through the practice of regular and diligent hand hygiene.

Frequent hand washing implies a prolonged exposure to water and other chemical

or physical agents and may induce several pathophysiologic changes, such as

epidermal barrier disruption, impairment of keratinocytes, the subsequent

release of proinflammatory cytokines, activation of the skin immune system, and

delayed-type hypersensitivity reactions. Adverse dermatologic effects, such as

excessive skin dryness or even contact dermatitis (particularly the irritant

subtype and, to a lesser extent, the allergic subtype), can occur, especially in

individuals with a history of atopic dermatitis. These skin conditions are

perfectly manageable, and applying a moisturizer immediately after washing hands

or after using a portable hand sanitizer is the cornerstone in preventing the

development of eczematous changes in the hands. In the current global context,

the potential occurrence of these dermatological adverse events should in no way

cause people to deviate from strict hand hygiene rules.

DOI: 10.7759/cureus.7506

PMCID: PMC7195203

PMID: 32373409

Conflict of interest statement: The authors have declared that no competing

interests exist.

4. Am J Clin Dermatol. 2020 Jun;21(3):307-311. doi: 10.1007/s40257-020-00514-2.

Managing Cutaneous Immune-Mediated Diseases During the COVID-19 Pandemic.

Torres T(1)(2), Puig L(3).

Author information:

(1)Department of Dermatology, Centro Hospitalar Universitário Do Porto, Porto,

Portugal. torres.tiago@outlook.com.

(2)Instituto de Ciências Biomédicas Abel Salazar, University of Porto, Porto,

Portugal. torres.tiago@outlook.com.

(3)Department of Dermatology, Hospital de La Santa Creu I Sant Pau, Barcelona,

Spain.

Coronavirus disease 2019 (COVID-19) is a clinical syndrome caused by a novel

coronavirus called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

COVID-19 has spread rapidly worldwide and has been shown to have a wide spectrum

of severity. COVID-19 has become a public health emergency of relevant

international concern, and it was declared a pandemic by the World Health

Organization on 11 March, 2020. SARS-CoV-2 infection in severe cases involves

the host response as an important contributor to the disease process and tissue

damage, mainly due to dysregulated and excessive innate immune responses. The

primary immune response leads to viral clearance in the majority of cases.

However, in a subgroup of patients, the secondary immune response may be

exaggerated, leading to inflammatory-induced lung injury and other complications

including pneumonitis, acute respiratory distress syndrome, respiratory failure,

shock, organ failure, and potentially death. Several cutaneous immune-mediated

diseases, including psoriasis, atopic dermatitis, and hidradenitis suppurativa,

are therapeutically managed with biologic and non-biologic immunosuppressive and

immunomodulatory drugs. The outbreak of COVID-19 affects the management of these

chronic conditions, not only for those who are already receiving treatment but

also for those who are about to start a new treatment to control their disease.

In this article, the management of cutaneous immune-mediated diseases during the

COVID-19 pandemic is discussed.

DOI: 10.1007/s40257-020-00514-2

PMCID: PMC7147535

PMID: 32277351 [Indexed for MEDLINE]

Conflict of interest statement: Tiago Torres has received consultancy and/or

speaker’s honoraria from and/or participated in clinical trials sponsored by

AbbVie, Amgen, Arena Pharmaceuticals, Boehringer Ingelheim, Bristol Myers

Squibb, Celgene, Janssen, Biocad, LEO Pharma, Eli Lilly, MSD, Novartis, Pfizer,

Samsung-Bioepis, Sanofi-Genzyme, and Sandoz. Luis Puig has received consultancy

and/or speaker’s honoraria from and/or participated in clinical trials sponsored

by AbbVie, Almirall, Amgen, Baxalta, Biogen, Boehringer Ingelheim, Celgene,

Gebro, Janssen, LEO Pharma, Eli Lilly and Company, Merck-Serono, MSD, Mylan,

Novartis, Pfizer, Regeneron, Roche, Sandoz, Samsung-Bioepis, Sanofi, and UCB.

5. J Allergy Clin Immunol Pract. 2020 May;8(5):1477-1488.e5. doi:

10.1016/j.jaip.2020.03.012. Epub 2020 Mar 26.

COVID-19: Pandemic Contingency Planning for the Allergy and Immunology Clinic.

Shaker MS(1), Oppenheimer J(2), Grayson M(3), Stukus D(3), Hartog N(4), Hsieh

EWY(5), Rider N(6), Dutmer CM(5), Vander Leek TK(7), Kim H(8), Chan ES(9), Mack

D(10), Ellis AK(11), Lang D(12), Lieberman J(13), Fleischer D(5), Golden

DBK(14), Wallace D(15), Portnoy J(16), Mosnaim G(17), Greenhawt M(18).

Author information:

(1)Dartmouth-Hitchcock Medical Center, Section of Allergy and Immunology,

Lebanon, NH; Dartmouth Geisel School of Medicine, Hanover, NH.

(2)UMDMJ Rutgers University School of Medicine, Newark, NJ.

(3)Nationwide Children's Hospital, The Ohio State University School of Medicine,

Columbus, Ohio.

(4)Spectrum Health Helen DeVos Children's Hospital, Grand Rapids, Mich.

(5)Children's Hospital Colorado, University of Colorado School of Medicine,

Aurora, Colo.

(6)The Texas Children's Hospital, Section of Immunology, Allergy, and

Retrovirology and the Baylor College of Medicine, Houston, Texas.

(7)Pediatric Allergy and Asthma, Department of Pediatrics, University of

Alberta, Edmonton, AB, Canada.

(8)Western University and McMaster University, London, ON, Canada.

(9)BC Children's Hospital, The University of British Columbia, Vancouver, BC,

Canada.

(10)McMaster University, Hamilton, ON, Canada; Halton Pediatric Allergy,

Burlington, ON, Canada.

(11)Division of Allergy and Immunology, Department of Medicine, Queen's

University, Kingston, ON, Canada.

(12)Department of Medicine, Section of Allergy and Immunology, Cleveland Clinic,

Cleveland, Ohio.

(13)Division of Allergy and Immunology, The University of Tennessee, Memphis,

Tenn.

(14)Division of Allergy and Clinical Immunology, John Hopkins University School

of Medicine, Baltimore, Md.

(15)Nova Southeastern University College of Allopathic Medicine, Fort

Lauderdale, Fla.

(16)Children's Mercy, University of Missouri-Kansas City School of Medicine,

Kansas City, Mo.

(17)Division of Pulmonary, Allergy and Critical Care, Department of Medicine,

NorthShore University Health System, Evanston, Ill.

(18)Children's Hospital Colorado, University of Colorado School of Medicine,

Aurora, Colo. Electronic address: Matthew.Greenhawt@childrenscolorado.org.

Comment in

J Allergy Clin Immunol Pract. 2020 May;8(5):1475-1476.

J Allergy Clin Immunol Pract. 2020 Jul - Aug;8(7):2452-2453.

J Paediatr Child Health. 2020 Jun;56(6):995.

In the event of a global infectious pandemic, drastic measures may be needed

that limit or require adjustment of ambulatory allergy services. However, no

rationale for how to prioritize service shut down and patient care exists. A

consensus-based ad-hoc expert panel of allergy/immunology specialists from the

United States and Canada developed a service and patient prioritization

schematic to temporarily triage allergy/immunology services. Recommendations and

feedback were developed iteratively, using an adapted modified Delphi

methodology to achieve consensus. During the ongoing pandemic while social

distancing is being encouraged, most allergy/immunology care could be

postponed/delayed or handled through virtual care. With the exception of many

patients with primary immunodeficiency, patients on venom immunotherapy, and

patients with asthma of a certain severity, there is limited need for

face-to-face visits under such conditions. These suggestions are intended to

help provide a logical approach to quickly adjust service to mitigate risk to

both medical staff and patients. Importantly, individual community circumstances

may be unique and require contextual consideration. The decision to enact any of

these measures rests with the judgment of each clinician and individual health

care system. Pandemics are unanticipated, and enforced social

distancing/quarantining is highly unusual. This expert panel consensus document

offers a prioritization rational to help guide decision making when such

situations arise and an allergist/immunologist is forced to reduce services or

makes the decision on his or her own to do so.

DOI: 10.1016/j.jaip.2020.03.012

PMCID: PMC7195089

PMID: 32224232 [Indexed for MEDLINE]

6. J Eur Acad Dermatol Venereol. 2020 Jun 25:10.1111/jdv.16774. doi:

10.1111/jdv.16774. Online ahead of print.

Cutaneous manifestations of SARS-CoV-2 infection: a clinical update.

Gisondi P(1), PIaserico S(2), Bordin C(1), Alaibac M(2), Girolomoni G(1), Naldi

L(3)(4).

Author information:

(1)Section of Dermatology and Venereology, Department of Medicine, University of

Verona, Verona, Italy.

(2)Section of Dermatology, Department of Medicine, University of Padua, Padua,

Italy.

(3)Division of Dermatology, San Bortolo Hospital, Vicenza, Italy.

(4)Centro Studi GISED, Bergamo, Italy.

On 11 March 2020, the World Health Organization (WHO) has declared the novel

coronavirus disease (COVID-19) a global pandemic, caused by the severe acute

respiratory syndrome coronavirus 2 (SARS-CoV-2 virus). A consistent number of

case reports and clinical series have been already published describing a

complex spectrum of skin manifestations associated with the SARS-CoV-2

infection. We carried out a review of the English-language literature up to 20

May 2020, reporting original cases or case series of the cutaneous

manifestations of SARS-CoV-2 virus infection. The following databases were

consulted: PubMed, Embase, Google Scholar and ResearchGate. The search of papers

was conducted by using the key term 'COVID-19' or 'SARS-CoV-2' or 'coronavirus'

combined with each of the following: 'skin', 'cutaneous', 'dermatologic' or

'dermatology', 'manifestation', 'lesions', or 'rash'. The patterns of

dermatological manifestations associated with SARS-CoV-2 infection could be

classified into four categories: exanthema (varicella-like, papulo-vesicular and

morbilliform rash), vascular (chilblain-like, purpuric/petechial and livedoid

lesions), urticarial and acro-papular eruption. Lastly, other skin

manifestations to be considered are the cutaneous adverse reactions to the drugs

prescribed for the treatment of COVID-19. Whether SARS-CoV-2 infection can

directly cause a worsening of chronic inflammatory diseases such as psoriasis or

atopic dermatitis remains to be determined. Dermatology's outlook in the

COVID-19 pandemic is multidimensional.

DOI: 10.1111/jdv.16774

PMCID: PMC7362144

PMID: 32585074

Atopic Dermatitis, COVID-19 and Hand Dermatitis

1. Dermatol Ther. 2020 May 5:e13509. doi: 10.1111/dth.13509. Online ahead of print.

Dermatological diseases presented before COVID-19: Are patients with psoriasis

and superficial fungal infections more vulnerable to the COVID-19?

Kutlu Ö(1), Metin A(1).

Author information:

(1)Uşak University, Department of Dermatology and Venereology, School of

Medicine, Uşak, Turkey.

Recent studies have focused on the comorbid conditions of the COVID-19.

According to the current studies, numerous diseases including lung disease,

cardiovascular disease and immunosuppression appear to be at higher risk for

severe forms of the COVID-19. To date, there are no data in the literature on

the comorbid dermatologic diseases and COVID-19. We tried to analyze the

previous dermatological comorbidity of 93 patients with COVID-19 (51 males, 42

females) who presented to the dermatology outpatient clinics for the last

3 years. The most common dermatologic diseases in patients with COVID-19 who

have dermatologic diseases for the last 3 years were superficial fungal

infections (24, 25.8%), seborrheic dermatitis (11, 11.8%), actinic keratosis

(10, 10.8%), psoriasis (6, 6.5%), and eczema (6, 6.5%), respectively. In

addition, the number of COVID-19 patients who presented to dermatology in the

last 3 months was 17 (11 men, 6 women). The median age of these patients was 58

(minimum 18, maximum 80) years, and the most common dermatologic diseases before

diagnosed COVID-19 were superficial fungal infections (5, 25%), psoriasis (4,

20%), and viral skin diseases (3, 15%). The possible similarity between

cutaneous and mucosal immunity and immunosuppression suggests that patients with

some dermatologic diseases especially superficial fungal infections and

psoriasis may be more vulnerable to the COVID-19.

DOI: 10.1111/dth.13509

PMCID: PMC7261987

PMID: 32367558

2. Contact Dermatitis. 2020 May 26:10.1111/cod.13618. doi: 10.1111/cod.13618.

Online ahead of print.

Onset of occupational hand eczema among healthcare workers during the SARS-CoV-2

pandemic: Comparing a single surgical site with a COVID-19 intensive care unit.

Guertler A(1), Moellhoff N(2), Schenck TL(2), Hagen CS(2), Kendziora B(1),

Giunta RE(2), French LE(1), Reinholz M(1).

Author information:

(1)Department of Dermatology and Allergy, University Hospital, LMU, Munich,

Germany.

(2)Division of Hand, Plastic and Aesthetic Surgery, University Hospital, LMU,

Munich, Germany.

BACKGROUND: As a result of the COVID-19 outbreak, hygiene regulations have been

revised and hand sanitation has been intensified.

OBJECTIVE: To investigate the onset of hand eczema during the COVID-19 pandemic

in healthcare workers (HCWs) directly involved in intensive care of COVID-19

patients and HCWs without direct contact with COVID-19 patients. Hereby, we aim

at increasing awareness about occupational hand eczema and preventive measures

that can be adopted.

METHOD: A survey was distributed amongst 114 HCWs at a single surgical centre

and at a COVID-19 intensive care unit of the university hospital Ludwig

Maximilian University Munich, Germany. Participants were questioned about the

daily frequency of hand hygiene prior to and during the pandemic. Participants

self-reported the onset of hand eczema and associated symptoms.

RESULTS: Our study revealed a significant increase in hand washing,

disinfection, and use of hand cream across all participants (P-value <.001),

regardless of having direct contact with COVID-19 patients. A high prevalence of

symptoms associated with acute hand dermatitis of 90.4% was found across all

HCWs, whereas hand eczema itself was underreported (14.9%).

CONCLUSION: The increase in hand sanitation during the COVID-19 pandemic impairs

the skin of the hands across all HCWs, independent of direct intensive care of

affected patients.

DOI: 10.1111/cod.13618

PMCID: PMC7283680

PMID: 32452036

3. Dermatol Ther. 2020 Jun 1:10.1111/dth.13738. doi: 10.1111/dth.13738. Online

ahead of print.

Influence of COVID-19 pandemic on hospitalizations at the tertiary dermatology

department in south-west Poland.

Białynicki-Birula R(1), Siemasz I(1), Otlewska A(1), Matusiak Ł(1), Szepietowski

JC(1).

Author information:

(1)Department of Dermatology, Venereology and Allergology, Wroclaw Medical

University. Wroclaw, Poland.

New virus SARS-Cov-2 infection has spread over the world affecting all daily

activities, including functioning of health services. Due to pandemic many

hospitals were ordered to re-organize their work. The aim of the current report

was to evaluate the influence of COVID-19 pandemic on the hospitalizations at

the tertiary dermatology department in south-west Poland. Two corresponding

periods of 2019 and 2020 were compared in aspect of number of hospitalizations,

sex and age profile of inpatients. We clearly showed a significant reduction of

hospitalized patients during the pandemic period, with marked reduction of

female patients. Moreover, the significant decrease of admissions to dermatology

ward was observed within children and patients older than 70 years. Patients

with chronic inflammatory dermatoses (eg, atopic dermatitis, eczemas, lichen

planus, pityriasis rubra pilaris) were less often hospitalized during the

pandemic period. In contrast, patients suffering from dermatitis due to

substances taken internally, erysipelas, syphilis and primary cutaneous

lymphomas constituted significantly higher rate of hospitalized subjects in

DOI: 10.1111/dth.13738

PMCID: PMC7300546

PMID: 32478949

4. J Eur Acad Dermatol Venereol. 2020 Jun 2. doi: 10.1111/jdv.16695. Online ahead

of print.

Hand Eczema Pandemic Caused by SARS-CoV-2 Hygiene Measures: The Setup of a Hand

Eczema Helpline for Hospital Personnel.

Greveling K(1), Kunkeler ACM(1).

Author information:

(1)Erasmus Medical Center, Dermatology department, Rotterdam, The Netherlands.

Hand eczema, also known as hand dermatitis, often results from a combination of

causes, including genetics (atopic constitution), irritating substances and

contact allergens. The novel severe acute respiratory syndrome coronavirus 2

(SARS-CoV-2) causes coronavirus disease 2019 (COVID-19). As current evidence

suggests that SARS-CoV-2 can be transmitted through contaminated hands, the

World Health Organization recommends frequent handwashing with soap and water,

or hand-rubbing with an alcohol based hand rub.

DOI: 10.1111/jdv.16695

PMID: 32488925

COVID-19 and Atopic Dermatitis

1. Br J Dermatol. 2020 Apr 29. doi: 10.1111/bjd.19161. Online ahead of print.

Global reporting of cases of COVID-19 in psoriasis and atopic dermatitis: an

opportunity to inform care during a pandemic.

Mahil SK(1), Yiu ZZN(2), Mason KJ(2), Dand N(3), Coker B(4), Wall D(5)(6),

Fletcher G(6), Bosma A(7), Capon F(3), Iversen L(8), Langan SM(1)(9), Di Meglio

P(3), Musters A(7), Prieto-Merino D(9), Tsakok T(1), Warren RB(2), Flohr C(1),

Spuls P(7), Griffiths CEM(2), Barker J(1), Irvine AD(10), Smith CH(1);

Secure-AD, PsoPROTECT study groups.

Author information:

(1)St John's Institute of Dermatology, Guy's and St Thomas' NHS Foundation

Trust, London, SE1 9RT, UK.

(2)Dermatology Centre, Salford Royal NHS Foundation Trust, The University of

Manchester, Manchester Academic Health Science Centre, NIHR Manchester

Biomedical Research Centre, Manchester, M13 9PT, UK.

(3)Department of Medical and Molecular Genetics, School of Basic & Medical

Biosciences, Faculty of Life Sciences & Medicine, King's College London, London,

UK.

(4)NIHR Biomedical Research Centre at Guy's and St Thomas' NHS Foundation Trust,

London, SE1 9RT, UK.

(5)Hair Restoration Blackrock, Dublin, Ireland.

(6)National and International Skin Registry Solutions (NISR), Charles Institute

of Dermatology, Dublin, Ireland.

(7)Department of Dermatology, Amsterdam Public Health, Infection and Immunity,

UMC, University of Amsterdam, Amsterdam, The Netherlands.

(8)Department of Dermatology, Aarhus University Hospital, Aarhus C, Denmark.

(9)Faculty of Epidemiology, and Population Health, London , School of Hygiene

and Tropical Medicine, London, UK.

(10)St. James's Hospital, James's Street, Dublin, Ireland.

We wish to bring your attention to the PsoPROTECT (Psoriasis Patient Registry

for Outcomes, Therapy and Epidemiology of Covid-19 infecTion) and SECURE-AD

(Surveillance Epidemiology of Coronavirus Under Research Exclusion-Atopic

Dermatitis) registries; two urgent global initiatives that address an unmet need

for delineating the determinants of COVID-19 outcomes in the common cutaneous

immune-mediated inflammatory diseases (IMIDs) psoriasis and atopic dermatitis.

DOI: 10.1111/bjd.19161

PMID: 32348554

2. J Eur Acad Dermatol Venereol. 2020 Mar 29. doi: 10.1111/jdv.16411. Online ahead

of print.

European Task Force on Atopic Dermatitis (ETFAD) statement on severe acute

respiratory syndrome coronavirus 2 (SARS-Cov-2)-infection and atopic dermatitis.

Wollenberg A(1)(2), Flohr C(3), Simon D(4), Cork MJ(5), Thyssen JP(6)(7), Bieber

T(8), de Bruin-Weller MS(9), Weidinger S(10), Deleuran M(11), Taieb A(12), Paul

C(13), Trzeciak M(14), Werfel T(15), Seneschal J(16), Barbarot S(17), Darsow

U(18), Torrelo A(19), Stalder JF(20), Svensson √Ö(21), Hijnen D(22), Gelmetti

C(23), Szalai Z(24), Gieler U(25), De Raeve L(26), Kunz B(27), Spuls P(28), von

Kobyletzki LB(29)(30), F√∂lster-Holst R(10), Chernyshov PV(31), Cristen-Zaech

S(32), Heratizadeh A(15), Ring J(33)(34), Vestergaard C(11).

Author information:

(1)Department of Dermatology and Allergy, Ludwig-Maximilian University, Munich,

Germany.

(2)Department of Dermatology I, M√ºnchen Klinik Thalkirchner Strasse, Munich,

Germany.

(3)St John's Institute of Dermatology, King's College London and Guy's & St

Thomas' NHS Foundation Trust, London, UK.

(4)Department of Dermatology, Inselspital, Bern University Hospital, University

of Bern, Bern, Switzerland.

(5)Sheffield Dermatology Research. Department of Infection, Immunity and

Cardiovascular Disease, The University of Sheffield, Sheffield, UK.

(6)Department of Dermatology and Allergy, Herlev and Gentofte Hospital,

Hellerup, Denmark.

(7)Copenhagen Research Group for Inflammatory Skin (CORGIS), Hellerup, Denmark.

(8)Department of Dermatology and Allergy, Christine K√ºhne-Center for Allergy

Research and Education, University Hospital of Bonn, Germany.

(9)National Expertise Center of Atopic Dermatitis, Department of Dermatology and

Allergology, University Medical Center Utrecht, Utrecht, The Netherlands.

(10)Department of Dermatology and Allergy, University Hospital

Schleswig-Holstein, Kiel, Germany.

(11)Department of Dermatology, Aarhus University Hospital, Aarhus, Denmark.

(12)University of Bordeaux, Bordeaux, France.

(13)Department of Dermatology, Toulouse University, Toulouse, France.

(14)Department of Dermatology, Venereology and Allergology, Medical University

of Gdansk, Gdansk, Poland.

(15)Department of Dermatology and Allergy, Hannover Medical School, Hannover,

Germany.

(16)Department of Adult and Pediatric Dermatology, CHU Bordeaux, University of

Bordeaux, Bordeaux, France.

(17)Department of Dermatology, CHU, Nantes, France.

(18)Department of Dermatology and Allergy, Technical University of Munich,

Munich, Germany.

(19)Department of Dermatology, Hospital Infantil Ni√±o Jes√∫s, Madrid, Spain.

INRAE, F-44000, Nantes, France.

(21)Department of Dermatology, Skane University hospital, Malm√∂, Sweden.

(22)Department of Dermatology, Erasmus MC University Medical Center, Rotterdam,

The Netherlands.

(23)Department of Pathophysiology and Transplantation, University of Milan,

Head, Unit of Pediatric Dermatology, Milan, Italy.

(24)Department of Dermatology of Heim, P√°l National Children's Institute

Budapest, Budapest, Hungary.

(25)Department of Dermatology, University of Gie√üen and Marburg GmbH, Gie√üen,

Germany.

(26)Department of Dermatology, Universitair Ziekenhuis Brussel (UZB), Free

University of Brussels (VUB), Brussels, Belgium.

(27)Dermatologicum, Hamburg, Germany.

(28)Department of Dermatology, Amsterdam Public Health, Infection and Immunity,

Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.

(29)University Healthcare Research Center, Faculty of Medicine, Lund University,

Malm√∂, Sweden.

(30)Department of Occupational and Environmental Dermatology, Lund University,

Sk√•ne University Hospital, Malm√∂, Sweden.

(31)Department of Dermatology and Venereology, National Medical University,

Kiev, Ukraine.

(32)Pediatric Dermatology Unit, Departments of Dermatology and Pediatrics,

Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.

(33)Department of Dermatology and Allergy Biederstein, School of Medicine,

Technical University of Munich, Munich, Germany.

(34)Christiane-K√ºhne Center for Allergy Research and Education (CK-Care), Davos,

Switzerland.

Atopic dermatitis (AD) is a complex disease with elevated risk of respiratory

comorbidities.1,2 Severely affected patients are often treated with

immune-modulating systemic drugs.3,4 On March 11th 2020, the World Health

Organization declared the 2019 novel coronavirus severe acute respiratory

syndrome (SARS-Cov-2) epidemic to be a pandemic. The number of cases worldwide

is increasing exponentially and poses a major health threat, especially for

those who are elderly, immuno-compromised, or have comorbidities. This also

applies to AD patients on systemic immune-modulating treatment. In these days of

uncertainty, reallocation of medical resources, curfew, hoarding, and shutdown

of normal social life, patients, caregivers and doctors ask questions regarding

the continuation of systemic immune-modulating treatment of AD patients. The

ETFAD decided to address some of these questions here.

DOI: 10.1111/jdv.16411

PMID: 32223003

3. J Eur Acad Dermatol Venereol. 2020 Apr 24. doi: 10.1111/jdv.16527. Online ahead

of print.

Safety of dupilumab in severe atopic dermatitis and infection of Covid-19: two

case reports.

Ferrucci S(1), Romagnuolo M(1)(2), Angileri L(1)(2), Berti E(1)(2), Tavecchio

S(1)(2).

Author information:

(1)Dermatology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico,

Via Pace, 9, 20122, Milan, Italy.

(2)Department of Physiopathology and Transplantation, Universit√† degli Studi di

Milano, Milan, Italy.

Dupilumab is a fully human monoclonal antibody against the alfa subunit of

interleukin (IL)-4 receptor that blocks signalling from both IL-4 and IL-13,

which are key type 2 cytokines in the pathophysiology of atopic dermatitis (AD).

It shows good efficacy with a rapid response and good safety with few side

effects. In a paper of Deleuran et al. the authors showed long term safety and

efficacy of dupilumab; they reported viral upper respiratory tract infection,

cough and influenza in about 2% of patients.

DOI: 10.1111/jdv.16527

PMID: 32330323

4. Am J Clin Dermatol. 2020 Apr 10. doi: 10.1007/s40257-020-00514-2. Online ahead

of print.

Managing Cutaneous Immune-Mediated Diseases During the¬†COVID-19 Pandemic.

Torres T(1)(2), Puig L(3).

Author information:

(1)Department of Dermatology, Centro Hospitalar Universit√°rio Do Porto, Porto,

Portugal. torres.tiago@outlook.com.

(3)Department of Dermatology, Hospital de La Santa Creu I Sant Pau, Barcelona,

Spain.

Coronavirus disease 2019 (COVID-19) is a clinical syndrome caused by a novel

coronavirus called severe acute respiratory syndrome coronavirus 2¬†(SARS-CoV-2).